Rituximab pharmacokinetics in children and adolescents withde novointermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response

(2012) U. Jager et al.   HAEMATOLOGICA

Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study

(2012) Mitchell S. Cairo et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report

(2012) S Goldman et al.   LEUKEMIA

Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia

(2010) Andrea Meinhardt et al.   JOURNAL OF CLINICAL ONCOLOGY

Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-myoclonus Syndrome

(2010) Michael R. Pranzatelli et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

(2008) D. Dayde et al.   BLOOD